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Simian immunodeficiency virus of chimpanzees (SIVcpz) is the immediate precursor to human immunode-
ficiency virus type 1 (HIV-1), yet remarkably, the distribution and prevalence of SIVcpz in wild ape populations
are unknown. Studies of SIVcpz infection rates in wild chimpanzees are complicated by the species’ endangered
status and by its geographic location in remote areas of sub-Saharan Africa. We have developed sensitive and
specific urine and fecal tests for SIVcpz antibody and virion RNA (vRNA) detection and describe herein the
first comprehensive prevalence study of SIVcpz infection in five wild Pan troglodytes schweinfurthii communities
in east Africa. In Kibale National Park in Uganda, 31 (of 52) members of the Kanyawara community and 39
(of 145) members of the Ngogo community were studied; none were found to be positive for SIVcpz infection.
In Gombe National Park in Tanzania, 15 (of 20) members of the Mitumba community, 51 (of 55) members of
the Kasekela community, and at least 10 (of 20) members of the Kalande community were studied. Seven
individuals were SIVcpz antibody and/or vRNA positive, and two others had indeterminate antibody results.
Based on assay sensitivities and the numbers and types of specimens analyzed, we estimated the prevalence of
SIVcpz infection to be 17% in Mitumba (95% confidence interval, 10 to 40%), 5% in Kasekela (95% confidence
interval, 4 to 7%), and 30% in Kalande (95% confidence interval, 15 to 60%). For Gombe as a whole, the SIVcpz
prevalence was estimated to be 13% (95% confidence interval, 7 to 25%). SIVcpz infection was confirmed in five
chimpanzees by PCR amplification of partial pol and gp41/nef sequences which revealed a diverse group of
viruses that formed a monophyletic lineage within the SIVcpzPts radiation. Although none of the 70 Kibale
chimpanzees tested SIVcpz positive, we estimated the likelihood that a 10% or higher prevalence existed but
went undetected because of sampling and assay limitations; this possibility was ruled out with 95% certainty.
These results indicate that SIVcpz is unevenly distributed among P. t. schweinfurthii in east Africa, with foci or
“hot spots” of SIVcpz endemicity in some communities and rare or absent infection in others. This situation
contrasts with that for smaller monkey species, in which infection rates by related SIVs are generally much
higher and more uniform among different groups and populations. The basis for the wide variability in SIVcpz
infection rates in east African apes and the important question of SIVcpz prevalence in west central African
chimpanzees (Pan troglodytes troglodytes) remain to be elucidated.
The origin and evolutionary history of human immunodefi-
ciency virus type 1 (HIV-1) and the circumstances leading to
the AIDS pandemic remain important questions for our un-
derstanding of emerging infectious diseases. Chimpanzees
(Pan troglodytes) are widely regarded as a natural host for
simian immunodeficiency virus SIVcpz and as the simian
source of HIV-1, but the prevalence of SIVcpz in wild chim-
panzee populations is completely unknown (2, 25). Only eight
naturally infected chimpanzees have thus far been identified,
and of those, seven were studied in captivity (13, 18, 41, 42; E.
Nerrienet, unpublished data). One wild chimpanzee from
Gombe National Park in Tanzania was recently found to har-
bor SIVcpz (49). This seeming scarcity of SIVcpz in captive
and wild ape populations has raised questions as to whether
chimpanzees represent a true SIVcpz reservoir (59) or whether
a third as yet unidentified primate species might be a source for
both human and chimpanzee infections (10, 58).
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Chimpanzees are widely dispersed across sub-Saharan Af-
rica. Four subspecies with distinct, nonoverlapping ranges are
currently recognized on the basis of mitochondrial DNA
(mtDNA) analyses (21, 33). These include the western Pan
troglodytes verus, the Nigerian P. t. vellerosus, the central P. t.
troglodytes, and the eastern P. t. schweinfurthii (Fig. 1A). The
great majority of captive chimpanzees in US and European
primate centers are of the P. t. verus subspecies because they
were imported from west Africa (51). Although more than
1,500 of these apes have been screened, none have been found
to harbor SIVcpz (44; W. M. Switzer, B. Parekh, V. Shan-
mugam, V. Bhullar, S. Phillips, T. M. Folks, J. Ely, and W.
Heneine, 9th International Workshop on HIV Dynamics and
Evolution, Lake Arrowhead, Calif., 2002). Members of the P.
t. vellerosus subspecies occupy a smaller region in Nigeria and
Cameroon north of the Sanaga River (Fig. 1A). Their infection
status is unknown because very few have been tested (E. Nerr-
ienet, unpublished data). Only P. t. troglodytes and P. t. schwein-
furthii are known to be naturally infected with SIVcpz (13, 42,
49). We have explained the absence of SIVcpz from P. t. verus
by postulating that chimpanzees as a species acquired SIVcpz
infection after the geographic separation and isolation of P. t.
verus from the other subspecies (2, 26, 48, 49). Recent data
concerning the origin of SIVcpz are consistent with this inter-
pretation, indicating that SIVcpz is actually a recombinant of
ancestral viruses that infected west central African monkey
species upon which chimpanzees prey (3). Under this scenario,
P. t. troglodytes would have been the initial host of this recom-
binant virus and P. t. schweinfurthii would have become in-
fected subsequently by the eastward spread of the virus.
Whether SIVcpz might also have spread to P. t. vellerosus is not
known.
Although isolated instances of SIVcpz infection have been
documented in P. t. troglodytes and P. t. schweinfurthii, neither
chimpanzee subspecies has been studied systematically in its
natural habitat. Wild chimpanzees live in communities of 5 to
150 individuals in the forests of tropical Africa. They avoid
human contact, except in the rare instances in which they have
been habituated to the presence of human observers (60). Wild
chimpanzees are also highly endangered. Deforestation, habi-
tat destruction, and relentless poaching have reduced the pop-
ulation size from over 2 million to less than 120,000 individuals
in just 50 years (38). Invasive studies, such as sampling of blood
or other tissues, are thus neither practical nor ethical. As an
alternative, we have recently developed urine- and fecal-based
assays for detecting SIVcpz antibodies and virion RNA
(vRNA), and we have used these to screen a small number of
habituated chimpanzees in east Africa (49). Analysis of urine
samples from 24 wild chimpanzees from the Kanyawara com-
munity in Kibale National Park (Uganda) failed to detect ev-
idence of SIVcpz infection, whereas testing of only six apes
from the Kasekela community in Gombe National Park iden-
tified one chimpanzee (Ch-06) to be both urine antibody and
fecal vRNA positive. Subsequent molecular analyses con-
firmed SIVcpz infection in this individual (49) and even per-
mitted the amplification of a complete viral genome from fecal
samples (48). While these studies established the utility of the
noninvasive assays for the detection and characterization of
SIVcpz under field conditions, they did not examine the sen-
sitivity and specificity of the assays, nor did they address the
frequency of SIVcpz infection in these wild chimpanzee com-
munities.
In this paper, we describe a comprehensive field survey of
146 wild chimpanzees from five different communities in east
Africa. By sampling individuals from two national parks in
Uganda and Tanzania, we could examine the prevalence, ge-
netic diversity, and transmission patterns of SIVcpz in both
habituated and nonhabituated settings. Our data reveal foci of
SIVcpz endemicity in some but not all wild communities—an
unexpected finding that is distinctly different from comparable
studies of SIV infection in other nonhuman primate species for
which infection rates are generally high and uniform. The
reasons for the scattered distribution of SIVcpz and for its
overall low prevalence in east African chimpanzee populations
remain to be determined. Nonetheless, the seven new cases of
SIVcpz infection in Gombe double the number of known nat-
ural infections and formally establish chimpanzees as a natural
host and reservoir for SIVcpz.
MATERIALS AND METHODS
Captive chimpanzees. Fecal and/or urine samples were collected from 47
captive chimpanzees of known HIV-1 or SIVcpz infection status housed at
primate facilities in the United States (Yerkes National Primate Research Cen-
ter, Atlanta, Ga.; n  35), The Netherlands (Biomedical Primate Research
Centre, Rijswijk; n  9), and Cameroon (wildlife rescue centers; n  3). Fifteen
of these had been experimentally infected with HIV-1 more than a decade earlier
as part of AIDS research studies (Table 1). Although five had significantly
reduced CD4 counts (less than 200/mm3; normal range 1,000 to 2,500/mm3),
none exhibited signs of clinical illness (35, 36, 39). Fecal and urine samples were
also obtained from four SIVcpz-infected chimpanzees. Of these, Ch-No and
CAM13 were wild-caught in the Democratic Republic of Congo (DRC) and
Cameroon, respectively, and thus likely acquired SIVcpz infection naturally (E.
Nerrienet, unpublished data) (41); Ch-Ni was infected experimentally in captivity
by using blood from Ch-No (28); and CAM4 is believed to have been infected
from a naturally infected cage mate, CAM3 (13). Twenty-eight uninfected chim-
panzees served as negative controls (Table 1). A subset of the experimentally
infected apes was examined for microhematuria and proteinuria as well as occult
blood in stool, but all tested negative. All studies were carried out in strict
accordance with international guidelines for the ethical scientific use and hu-
mane care of primates in research (the Yerkes National Primate Research
Center is fully accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care International).
Wild chimpanzees. Fecal and urine samples were collected from wild chim-
panzee communities in Kibale and Gombe National Parks (Fig. 1). Kibale Na-
tional Park is located in western Uganda and has two major research sites,
Kanyawara and Ngogo (Fig. 1B). The Kanyawara community has been studied by
Wrangham and colleagues since 1987 and comprised 52 individuals at the time
of sampling (61). The Ngogo community has been studied continuously since
1995 and comprised about 145 individuals at the time of sampling (32, 57). Both
Kanyawara and Ngogo chimpanzees tolerate the presence of human observers at
close distances (5 to 10 m). All group members are individually known and
named, allowing for sample collection under direct observation. Field studies in
Kibale National Park were authorized by the Makerere University Biological
Field Station and the Uganda Wildlife authority.
Gombe National Park is located on the eastern shores of Lake Tanganyika in
Tanzania and is home to three chimpanzee communities (Fig. 1C). The largest,
Kasekela, is habituated and has been studied by Goodall since 1960 (22). Ha-
bituation of northern Mitumba community began in the 1980s, with most indi-
viduals identified by the mid-1990s. The southern Kalande community is not
habituated and thus is the least studied of all Gombe communities. The three
Gombe communities comprise a total of 95 individuals and have partially over-
lapping ranges (Fig. 1C). The Kasekela and Mitumba chimpanzees are moni-
tored daily, with particular individuals selected for all-day observation, and their
reproductive states and social interactions are recorded. For some of the more
recent Kasekela offspring, paternity has been determined by microsatellite anal-
ysis (12). Fieldwork in Gombe National Park was authorized by the Tanzania
Commission for Science and Technology, the Tanzania Wildlife Research Insti-
tute, and the Tanzania National Parks.
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FIG. 1. Location of wild chimpanzee study sites. (A) The locations of Kibale (Uganda) and Gombe (Tanzania) National Parks (indicated by
asterisks) are shown in relation to the range of the common chimpanzees in equatorial Africa (Copyright © 2001, Smithsonian Institution. Adapted
from reference 8 with permission). The four recognized chimpanzee subspecies are color coded. International borders (black lines) and major rivers
(blue lines) are shown. Uganda and Tanzania are highlighted. (B) Map of Kibale National Park, indicating the approximate ranges of the Kanyawara
(red) and Ngogo (blue) communities. The two communities are not adjacent, thus limiting direct contact between members. Black dots denote ranger
outposts. (C) Map of Gombe National Park, indicating the approximate ranges of the northern Mitumba (red), the main Kasekela (blue), and the
nonhabituated southern Kalande community (green). Gombe National Park is bordered by Lake Tanganyika to the east, and the rift escarpment
(1,500 m) to the west. Interactions between members of the different communities have been observed in regions of overlap.
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Sample collection and storage. Captive chimpanzees were sampled at the time
of cage cleaning, with fecal and urine samples frozen immediately and stored at
20°C until analysis. Wild chimpanzees from habituated communities were
sampled under direct observation, with date, time, and name of the particular
chimpanzee recorded. Urine (1 to 3 ml) was collected by placing plastic bags
under night nests or by pipetting from leaves. Aliquots were placed into sterile
tubes without additives and frozen within hours of collection. Stool samples (20
to 50 g) were also collected from known individuals under direct observation and
placed in 50-ml tubes with or without 20 ml of RNAlater (Ambion, Austin, Tex.).
RNAlater preserves nucleic acids (RNA and DNA), allowing storage and ship-
ment at room temperature without vRNA degradation, but precludes immuno-
blot analysis. Samples from the nonhabituated Kalande community, some of
which were estimated to be more than a day old at the time of collection, were
all preserved in RNAlater. Fecal samples not preserved in RNAlater were
frozen. All samples were analyzed under code, with the investigator perform-
ing immunoblot or RNA analyses unaware of the infection status of the study
subject.
Detection of urine and fecal antibodies by Western immunoblot analysis.



















C455 Yerkes Exp JC 0 4/99 0/4 0/2 — —
C487 Yerkes Exp LAV-Ib 698 4/99 3/4 0/2 — —
C463 Yerkes Exp LAV-I 123 4/99 2/4 1/2 1/1 0/1
C544 Yerkes Exp LAV-Ib/(EHO) 953 4/99 4/4 0/2 1/1 0/1
C550 Yerkes Exp LAV-Ib 95 4/99 2/2 1/2 1/1 1/1
C560 Yerkes Exp LAV-Ib/SF2 182 4/99 2/2 0/2 1/1 0/1
C459 Yerkes Exp LAV-I/NDK/NC 186 4/99 2/2 0/1 1/1 0/1
C552 Yerkes Exp LAV-Ib 1100 4/99 0/2 0/2 — —
C497 Yerkes Exp NDK 850 4/99 0/2 0/2 — —
C542 Yerkes Exp LAV-Ib 1241 4/99 1/2 0/2 — —
C534 Yerkes Exp NC/(ROD) 19 4/99 2/2 0/2 — —
Ch-La Rijswijk Exp LAI/HAN2 1700 7/99 3/3 0/3 3/3 0/3
Ch-On Rijswijk Exp HAN2 2300 7/99 1/3 0/3 3/3 0/3
Ch-Ma Rijswijk Exp LAI/HAN2 1300 7/99 2/3 0/3 3/3 0/3
Ch-Bu Rijswijk Exp LAI/HAN2 1000 7/99 2/3 0/3 3/3 0/3
SIVcpz infected
Ch-No Rijswijk Nat ANT 1400 7/99 7/9 7/9 3/3 1/3
Ch-Ni Rijswijk Exp ANT — 7/99 3/3 3/3 3/3 0/3
CAM4 Cameroon Cage CAM4 — 11/99 2/7 1/10 4/4 0/4
CAM13 Cameroon Nat CAM13 — 2/01 — 3/3 — —
Uninfected
C575 Yerkes None n/a 1330 4/99 0/4 — — —
C369 Yerkes None n/a — 4/99 0/2 — — —
C431 Yerkes None n/a 2552 4/99 0/2 — — —
C452 Yerkes None n/a — 4/99 0/2 — — —
C382 Yerkes None n/a — 4/99 0/2 — — —
C425 Yerkes None n/a 1035 4/99 0/2 — — —
C520 Yerkes None n/a 1220 4/99 0/2 — — —
C507 Yerkes None n/a — 4/99 0/2 — — —
C536 Yerkes None n/a 1850 4/99 0/2 — — —
C408 Yerkes None n/a — 4/99 0/2 — — —
C475 Yerkes None n/a — 4/99 0/2 — — —
C471 Yerkes None n/a — 4/99 0/2 — — —
C447 Yerkes None n/a — 4/99 0/2 — — —
C505 Yerkes None n/a 1600 4/99 0/2 — — —
C548 Yerkes None n/a 977 4/99 0/2 — — —
C400 Yerkes None n/a — 4/99 0/2 — — —
C407 Yerkes None n/a 772 4/99 0/2 — 0/1 —
C421 Yerkes None n/a — 4/99 0/2 — — —
C433 Yerkes None n/a 932 4/99 0/2 — — —
C202 Yerkes None n/a — 4/99 0/2 — — —
C494 Yerkes None n/a 2362 4/99 — — 0/1 —
C586 Yerkes None n/a 1815 4/99 — — 0/1 —
C222 Yerkes None n/a — 4/99 — — 0/1 —
C694 Yerkes None n/a — 5/01 — — 0/1 —
Ch-Ph Rijswijk None n/a — 7/99 0/3 — 0/3 —
Ch-Pe Rijswijk None n/a — 7/99 0/3 — 0/3 —
Ch-To Rijswijk None n/a — 7/99 0/3 — 0/3 —
CAM10 Cameroon None n/a — 11/99 — — 0/1 —
a Exp, experimental infection; Nat, natural infection; Cage, cage transmission; none, not infected with HIV-1 or SIVcpz; n/a, not applicable.
b CD4 counts per mm3 (normal range 1,000–2,500/mm3); —, specimens not available.
c Ab, antibody. Number of antibody-positive fecal and urine samples per total number tested as determined by ECL Western blot analysis (samples which yielded
a gp160 band, alone or in combination with other virus specific bands, or any three structural proteins exclusive of gp160, were scored antibody positive).
d Number of vRNA-positive fecal and urine samples per total number tested as determined by diagnostic RT PCR analysis (authenticity of amplification products
was confirmed by sequence analysis).
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Enhanced chemiluminescent Western blotting was performed as previously de-
scribed (49) by using commercially available HIV-1 nitrocellulose test strips
(Calypte Biomedical, Rockville, Md.). Fecal samples (2.5 g, frozen without
additives) were resuspended (33% [wt/vol]) in 1 immunoblot buffer (phos-
phate-buffered saline [PBS; pH 7.4], 5 mM EDTA, 0.05% [wt/vol] Tween 20, 0.15
mM NaN3, 1% [wt/vol] bovine serum albumin, and 0.01% [wt/vol] IGEPAL
detergent [Sigma Biochemicals, St. Louis, Mo.]), vortexed, and centrifuged at
13,800 g for 25 min at 4°C to pellet solid debris. Supernatants were transferred
to a new tube and centrifuged a second time at 4,000  g for 10 min at 4°C to
remove additional solid matter. Urine samples were tested without further pro-
cessing. Western blot strips were hydrated for 10 min in PBS-Tween containing
138 mM NaCl, 2.7 mM KCl, and 0.05% (wt/vol) Tween 20 (pH 7.4), blocked with
5% skim milk in PBS-Tween for 1 h at room temperature, incubated with 1 ml
of undiluted urine or clarified fecal extracts in 1 immunoblot buffer overnight
at 4°C on a rocker platform, reacted with goat anti-human immunoglobulin G
(IgG) (1:1,000) conjugated to horseradish peroxidase (Southern Biotechnology,
Birmingham, Ala.) for 1 h at room temperature, and developed by using an ECL
detection system (Amersham/Pharmacia Biotech, Piscataway, N.J.) on Hyper-
film-ECL. A subset of Western blots was also probed with goat anti-human Ig or
goat anti-human IgA secondary antibodies. A plasma sample from an HIV-1-
infected human was used as a positive control at dilutions of 1:10,000 and
1:100,000.
Nucleic acid extraction from chimpanzee fecal and urine samples. Fecal RNA
was extracted by using the RNAqueous-Midi kit (Ambion). Fecal aliquots (0.5 g
or 1 ml of a 1:1 suspension in RNAlater) were resuspended in 6 ml of lysis buffer,
vortexed, and centrifuged (16,000  g, 3 min) to remove solid debris. Clarified
supernatants were mixed with an equal volume of 64% ethanol and passed
through a glass fiber filter unit. Bound nucleic acids were eluted (1 ml), precip-
itated with LiCl2 to enrich for RNA and to remove potential PCR inhibitors,
pelleted, washed with 70% ethanol, air dried, and resuspended in 50 l of RNA
storage solution (Ambion).
Fecal DNA was extracted by using the QIAamp DNA Stool Mini Kit (QIA-
GEN, Valencia, Calif.). Briefly, 400 l of fecal sample (in RNAlater) was resus-
pended in stool lysis buffer, treated with InhibitEx to remove possible PCR
inhibitors, and spun. Supernatants were subjected to proteinase K digestion and
then loaded on microspin columns for DNA purification and concentration.
DNA was eluted in 100 l of elution buffer (10 mM Tris-Cl, pH 8.5), and 5-l
aliquots were used for mitochondrial DNA amplification and sex determinations
(see below).
Urine aliquots (1 ml) were ultracentrifuged (23,500  g, 1 h at 4°C) to pellet
virions and cellular components. Total nucleic acids (RNA and DNA) were
extracted from the pellets by using the Boom method (7), as adapted in the
NucliSens HIV-1 QT Kit (Organon-Teknika, Boxtel, The Netherlands), and the
final eluate was resuspended in 50 l of RNA storage solution (Ambion).
Amplification of SIVcpz vRNA by RT PCR. Diagnostic reverse transcriptase
PCR (RT PCR) was performed by using two sets of primer pairs based on
consensus HIV-1 and SIVcpz sequences (29). The pol primer set amplifies a
330-bp fragment in the conserved integrase region and consists of first-round
primers pol-F1 (5-CCAGCNCACAAAGGNATAGGAGG-3) and pol-R1 (5-
ACBACYGCNCCTTCHCCTTTC-3) and second-round primers pol-F2 (5-G
GAAGTGGATACTTAGAAGCAGAAGT-3) and pol-R2 (5-CCCAATCCC
CCCTTTTCTTTTAAAATT-3). The gp41/nef primer set amplifies a 740- to
790-bp fragment at the junction of gp41 and nef and consists of first-round
primers gp41/nef-F1 (5-AAATGGCTGTGGTATATAAAAAT-3) and gp41/
nef-R1 (5-CCCWTCCAGTCCCCCCTTTTC-3) and second-round primers
gp41/nef-F2 (5-GCTTAAGAAAGGTTAGGCAGGG-3) and gp41/nef-R2
(5-TCCCCCCTTTTCTTTTAAAAA-3). For cDNA synthesis, 10 l of the
fecal- or urine-derived nucleic acid solution was added to an RT PCR master mix
consisting of 1 Buffer II (Perkin-Elmer, La Jolla, Calif.), 5 mM MgCl2, 1 mM
dNTP, 5 mM dithiothreitol, 20 pmol of cDNA synthesis primer (either pol-R1 or
gp41/nef-R1), 20 U of RNase inhibitor (Promega, Madison, Wis.), and 100 U of
Superscript RT II (Gibco-BRL, Rockville, Md.); the mixture was then incubated
for 1 h at 42°C. Ten microliters of the cDNA was then added to a PCR mix
consisting of 1 Expand Buffer II (Roche Molecular Biochemicals, Indianapolis,
Ind.), 0.35 mM dNTP, 10 pmol of the corresponding primers for the first-round
PCR (F1/R1), 0.1 g of bovine serum albumin per ml, and 2.5 U of Expand
High-Fidelity Taq polymerase (Roche Molecular Biochemicals). PCR amplifi-
cations included 45 cycles of denaturation (94°C, 30 s), annealing (50°C, 30 s),
and elongation (68°C, 1 min) in a Perkin-Elmer 2400 thermocycler. Two micro-
liters of the first-round reaction was used for the nested PCR with the second-
round primers, F2/R2, by using the same thermocycling conditions. Amplified
products were gel purified (QIAGEN) and directly sequenced with an ABI
automated DNA sequencer by using the nested primers. Sequences were
analyzed with the Sequencher program (Gene Codes Corporation, Ann Ar-
bor, Mich.), and deposited at GenBank: SIVcpzTAN2 (AY181990, AY181991),
SIVcpzTAN3 (AY181988, AY181992), SIVcpzTAN4 (AY181989), and
SIVcpzTAN5 (AY181993). The full-length SIVcpzTAN1 sequence (AF447763)
has been reported previously (48).
Sensitivity and specificity calculations. Assay sensitivities and specificities
were calculated by using test results obtained under code from captive chimpan-
zees of known HIV-1 or SIVcpz infection status (Table 1). The sensitivity values
of antibody and vRNA detection in urine and fecal samples were determined as
the fraction of positive tests per total number of samples analyzed (rather than
number of individuals analyzed), with confidence limits determined given the
assumption of binomial sampling (Table 2). For these calculations, it was as-
sumed that successive test results from the same individual were not correlated.
The specificities of fecal and urine antibody detection were calculated by using
test results from uninfected chimpanzees. The specificity of vRNA detection in
both fecal and urine samples was deduced to be 100% since all amplification
products were subsequently sequence confirmed.
Although the sensitivity of urine antibody detection in the captive population
was 100%, subsequent field studies identified, from an SIVcpz-infected wild
chimpanzee (Ch-37), one urine sample that exhibited an indeterminant Western
blot result. Thus, of 21 urine samples from a total of six SIVcpz-infected chim-
panzees (Ch-No, Ch-Ni, CAM4, Ch-06, Ch-30, and Ch-37), only 20 met the
criteria for Western blot positivity. For the prevalence calculations, we therefore
used a more conservative estimate of 0.95 (for 20 of 21 samples) for the sensi-
tivity of the urine antibody test.
Prevalence estimations. The prevalence rates of SIVcpz infection in the five
wild communities were estimated by using the test sensitivities determined for
SIVcpz (not HIV-1-)-infected apes. For each chimpanzee, the probability of
infection being detected, if it was truly infected, was calculated, taking into
consideration the different types and numbers of specimens analyzed. The prev-
alence for the community was then estimated as the number of chimpanzees that
tested positive divided by the number of chimpanzees expected (given the assay
sensitivities) to test positive, assuming that all individuals were truly infected. For
these calculations, it was again assumed that the probabilities of a positive test
result in successive samples from an infected chimpanzee were not correlated.
For the Kanyawara and Ngogo communities, where no infected individuals
were identified, the upper confidence limits on the rate of infection were calcu-
TABLE 2. Sensitivity and specificity of antibody and vRNA detection in feces and urine, respectivelya
Detection method
HIV-1-infected chimpanzees SIVcpz-infected chimpanzees Uninfected chimpanzees
Individuals Samples Sensitivity(95% CI) Individuals Samples
Sensitivity




Urine 9/9 17/17 1.00 (0.84–1.00) 3/3 10/10 1.00 (0.74–1.00) 0/9 0/15 1.00 (0.82–1.00)
Feces 12/5 26/42 0.62 (0.50–0.74) 3/3 12/19 0.63 (0.47–0.83) 0/23 0/51 1.00 (0.94–1.00)
RT PCR (vRNA)
Urine 1/9 1/17 0.06 (0.02–0.25) 1/3 1/10 0.10 (0.04–0.39) NDb ND 1.00
Feces 2/15 2/33 0.06 (0.02–0.18) 4/4 14/25 0.56 (0.42–0.73) ND ND 1.00
a Sensitivity and specificity estimates are based on the number of samples rather than the number of individuals tested (each with 95% confidence interval [CI]).
b ND, not done.
c Specificity of vRNA detection by RT PCR is 100%, since all amplification products are sequence confirmed.
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lated as the prevalences that would give only a 5% chance of having missed
infection, given the number and types of samples analyzed and the particular
tests used. For these communities, it was assumed that the total Kibale popula-
tion size was large and unknown. For the more isolated Gombe chimpanzees
(31), the actual number of individuals per community was used, which was 55 for
Kasekela, 20 for Mitumba, and 20 for Kalande at the time of sampling. For these
populations, the calculations of upper and lower confidence limits were based on
the number of individuals per community who could be infected and yet would
have a greater than 5% chance of showing as few or as many infected individuals
as were detected, respectively.
For the nonhabituated Kalande community, 25 fecal samples from an un-
known number of chimpanzees were available. It was thus assumed that each of
the 20 chimpanzees in that community was sampled a Poisson number of times,
with a mean number of samples of 1.25 per chimpanzee. The probability that an
infected chimpanzee would be detected as being positive was estimated, and the
prevalence was then calculated as the number of infected chimpanzees detected
divided by the number of chimpanzees expected to be positive, assuming that all
were truly infected. The upper and lower bounds of the possible numbers of
chimpanzees infected (out of 20) in that community were also calculated. These
were the largest, or smallest, number of infected chimpanzees that would have a
greater than 5% chance of showing as few or as many infected chimpanzees as
were detected, respectively.
Subspecies and sex determinations. To confirm the subspecies origin of fecal
samples from nonhabituated communities, a 450-bp region of the mtDNA ge-
nome (D loop) was amplified as previously described (33) by using primers
L15997 (5-CACCATTAGCACCCAAAGCT-3) and H16498 (5-CCTGAAGT
AGGAACCAGATG-3). The resulting products were sequenced directly with
L15997 used as the sequencing primer. For sex determination, a region of the
amelogenin gene was targeted which is known to contain a deletion near the
centromere of the Y, but not of the X, chromosome (16). Primers AMEL-F
(5-CTGATGGTTGGCCTCAAGCCTGTG-3) and AMEL-R (5-TAAAGAG
ATTCATTAACTTGACTG-3) amplify a 977-bp fragment from the X chromo-
some and amplify a 788-bp fragment from the Y chromosome (16). As a con-
sequence, genomic DNA from a male chimpanzee yields two amplification
products (977 and 788 bp, respectively), while genomic DNA from a female
chimpanzee only yields one fragment (977 bp). PCR conditions were the same as
for mtDNA amplification (33), except that an annealing temperature of 55°C was
used and 55 amplification cycles were performed.
Phylogenetic methods. Viral and mtDNA sequences were aligned by using
CLUSTAL W (viral sequences were aligned bearing in mind their predicted
protein sequences) (53). Gaps in any of the sequences or ambiguous areas were
excluded from all comparisons. Phylogenies were inferred by the neighbor-
joining method (47) and by the maximum likelihood method with a gamma
distribution used to allow for variation in the substitution rate between sites
(Phylogenetic Analysis by Maximum Likelihood [PAML], software version 3.0b;
University College London, London, United Kingdom).
RESULTS
Fecal- and urine-based methods for SIVcpz antibody and
vRNA detection. To validate the urine- and fecal-based SIVcpz
detection approaches, assay sensitivities and specificities were
determined in captive chimpanzees of known infection status.
Figure 2 shows representative enhanced chemiluminescent
(ECL) Western blots of fecal suspensions and urine samples
from captive chimpanzees chronically infected with HIV-1 or
SIVcpz and from uninfected controls (see Table 1 for charac-
teristics of captive chimpanzees and summary of test results).
HIV-1 was used as the test antigen because of its commercial
availability and its close genetic and antigenic relatedness to
SIVcpz (2, 42). Fecal and urine specimens from both HIV-1-
and SIVcpz-infected chimpanzees contained readily detectable
antibodies which were of the IgG class and were directed
against multiple HIV-1 proteins. However, fecal antibodies
were generally lower in titer and produced a more variable
banding pattern (Fig. 2A) than urine antibodies (Fig. 2B).
Moreover, there was substantially more variability among dif-
ferent individuals and between different samples from the
same individual in fecal blots than in urine blots, again likely as
a consequence of differences in antibody titers. The use of
anti-Ig secondary antibodies did not enhance HIV-1 or SIVcpz
antibody detection, and anti-IgA secondary antibodies were
generally nonreactive (data not shown). Importantly, speci-
mens from uninfected chimpanzees did not react with any viral
antigens.
A total of 112 fecal samples and 42 urine samples from 46
captive chimpanzees of known infection status were analyzed
by ECL immunoblotting in order to develop criteria for posi-
tive, negative, and indeterminant reactivity and to assess the
sensitivity and specificity of the assays (all analyses were per-
formed under code). Western blots exhibiting a band corre-
sponding to the HIV-1 envelope glycoprotein gp160 alone or
in combination with any other viral band, or reactivity to any
three structural proteins exclusive of gp160, were scored as
positive, similar to the interpretive guidelines of commercial
HIV-1 urine and serum immunoassays (9, 54). The absence of
viral bands was scored negative, and samples which did not
meet either criterion were considered indeterminant. By using
these criteria, the sensitivity of fecal antibody detection was
62% for specimens from HIV-1-infected chimpanzees and
63% for specimens from SIVcpz-infected chimpanzees (Table
2). For urine antibody detection, the sensitivity was 100% for
both HIV-1- and SIVcpz-infected chimpanzees. Specificity was
100% in all instances. None of the fecal or urine samples from
infected or uninfected chimpanzees exhibited indeterminant or
false-positive banding patterns.
We also investigated whether HIV-1 or SIVcpz nucleic acids
could be detected in urine and fecal specimens from infected
chimpanzees by nested PCR amplification. A genomic region
in the viral pol gene (330 bp), highly conserved among diver-
gent SIVcpz and HIV-1 strains, was chosen for analysis. Viral
RNA, but not DNA, was detected in both feces and urine from
a proportion of infected individuals (Tables 1 and 2), suggest-
ing that viral nucleic acids were present in the form of virions
and not in infected cells or as free nucleic acid. However, viral
RNA was more frequently detected in feces (6 of 19 individuals
positive) than in urine (only 2 of 12 individuals positive) and
much more frequently in feces of SIVcpz-infected chimpan-
zees (4 of 4) than in HIV-1-infected chimpanzees (2 of 15). In
fact, 14 of 25 fecal samples from SIVcpz-infected chimpanzees
were found to be vRNA positive, compared with only 2 of 33
samples from HIV-1-infected apes. This difference was statis-
tically significant (P  0.002) and suggested a sensitivity of
56% for fecal vRNA detection in naturally infected chimpan-
zees. Although this sensitivity was lower than the sensitivity of
both urine and fecal antibody detection (Table 2), the fact that
all four SIVcpz-infected chimpanzees had at least one fecal
sample that was positive by RT PCR indicated to us that vRNA
analyses would be useful for confirmation and molecular iden-
tification of SIVcpz infection as well as for screening, if serial
specimens could be collected and tested.
Noninvasive survey of wild chimpanzees in Kibale National
Park. In a previous study, we failed to identify SIVcpz infection
among 24 members of the Kanyawara community in Kibale
National Park (49). To examine whether this was due to insuf-
ficient sampling, we obtained additional specimens from Kan-
yawara and expanded our survey to a second, larger commu-
nity, termed Ngogo (Fig. 1B). Importantly, the ranges of the
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Kanyawara and Ngogo communities are not adjoining, thus
limiting direct interactions between their members. Ngogo is
also unusual in that it comprises the largest community with
the highest number of male members known to exist in the wild
(32, 57). This is believed to be responsible for the social and
behavioral differences that distinguish Ngogo chimpanzees
from other wild ape communities (57). Screening both Ngogo
and Kanyawara chimpanzees thus ensured a more representa-
tive sampling of the larger Kibale population, which includes
still other communities. Both Ngogo and Kanyawara chimpan-
zees are habituated, permitting repeated sampling from known
individuals under direct observation (34, 57, 61).
FIG. 2. Detection of HIV-1- and SIVcpz-specific antibodies in chimpanzee fecal and urine samples. Fecal (A) and urine (B) specimens from
captive chimpanzees chronically infected with either HIV-1 or SIVcpz, and specimens from uninfected controls, were tested by ECL Western
immunoblot analysis for the presence of virus-specific antibodies. Chimpanzees are identified by code number (additional information for each
individual is provided in Table 1); Ch-No and Ch-Ni are infected with the highly divergent SIVcpzANT strain (28, 55). Serial samples from the
same individual are identified in parentheses. Molecular weights of HIV-1-specific proteins are indicated. The banding pattern of plasma from an
HIV-1-infected human (analyzed at dilutions of 1:10,000 and 1:100,000) is shown for positive control.
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Study subjects, sex, sample collection dates, numbers of sam-
ples tested from each chimpanzee, and the results of tests for
SIVcpz antibodies and for vRNA are summarized in Table 3.
For Kanyawara, a total of 80 urine specimens were obtained
from 31 chimpanzees, representing all of the adult and ado-
lescent males as well as 82% of the adult and adolescent
females (the community comprised a total of 52 members at
the time of study). All tested negative for SIVcpz antibodies
(Table 3). Moreover, at least one urine sample from each
individual was also subjected to RT PCR analysis and found to
be negative for vRNA. Similarly, none of 39 chimpanzees from
the Ngogo community tested positive for SIVcpz infection (the
community comprised a total of 145 members at the time of
study). A total of 45 urine and 58 fecal samples from 32 adult
and adolescent males and 7 adult and adolescent females were
negative for SIVcpz antibodies and vRNA, respectively (Table
3). This was also true for an additional set of 16 urine and 7
fecal samples for which the respective donors could not be
determined with certainty (data not shown). Thus, screening
more than 70 wild chimpanzees from two different communi-
ties, including 61 individuals with the highly sensitive urine
antibody test, failed to yield evidence for SIVcpz infection in
Kibale National Park.
Noninvasive survey of wild chimpanzees in Gombe National
Park. In contrast to Kibale, our previous survey had identified
a single SIVcpz-infected chimpanzee in Gombe National Park
(49). This individual was one of six tested from the Kasekela
community, which is the largest in Gombe and currently com-
prises 55 individuals (Fig. 1C). We thus targeted the remaining
members of this community for additional fecal and urine
collections but also screened individuals from the neighboring
Mitumba and Kalande communities (Fig. 1C). Both of these
are much smaller than Kasekela, each comprising only 20 in-
dividuals, and the southern Kalande community is not ha-
bituated. The three communities have adjoining ranges, thus
providing an opportunity for direct interaction among chim-
panzees mainly in the form of border disputes and the migra-
tion of adolescent and adult females. Because of extensive de-




























ARd F 2/98–10/98 0/4 0/2
BLd F 2/99 0/1 0/1
EKd F 4/99 0/1 0/1
KLd F 3/98–6/98 0/2 0/1
ALd F 9/98–11/98 0/4 0/1
LPd F 12/97–2/98 0/3 0/1
MUd F 6/99 0/1 0/1
NLd F 4/98 0/1 0/1
OUd F 4/98–9/98 0/4 0/1
PUd F 6/99 0/1 0/1
TGd F 4/98–8/98 0/3 0/1
AS F 2/98 0/1 0/1
NE F 10/98 0/1 0/1
LR F 4/98 0/1 0/1
FG F 2/98 0/1 0/1
FN F 2/98 0/1 0/1
GO F 12/98 0/1 0/1
UM F 2/00 0/1 0/1
BFd M 3/98–3/98 0/4 0/1
BBd M 12/97–7/98 0/4 0/3
MSd M 1/98–10/98 0/3 0/1
AJd M 1/98–9/98 0/4 0/1
KKd M 1/98–8/98 0/5 0/1
LBd M 3/98–9/98 0/4 0/1
LKd M 3/98–11/98 0/3 0/2
SLd M 8/98–11/98 0/3 0/1
SYd M 2/98–11/98 0/3 0/1
STd M 2/98–11/98 0/5 0/2
TUd M 2/98–11/98 0/6 0/1
PGd M 2/99 0/1 0/1
YBd M 3/98–11/98 0/3 0/2
Total 18F/13M 12/97–2/00 0/80 0/37
Ngogo community
NG-01 F 3/02 0/1 0/1
NG-02 F 3/02 — 0/1
a M, male; F, female.
b Number of antibody-positive (Ab pos) urine samples per total number tested as determined by ECL-based immunoblot analysis (see Materials and Methods).
—, specimens not available.
c Number of vRNA-positive urine or fecal samples per total number tested as determined by diagnostic RT PCR.
d Individuals included in a previous study (49).
NG-03 F 4/02 0/1 0/1
NG-04 F 4/02 — 0/2
NG-05 F 4/02 — 0/1
NG-06 M 3/02–4/02 0/2 0/1
NG-07 M 3/02 0/1 0/3
NG-08 M 3/02 0/1 0/3
NG-09 M 3/02–4/02 0/1 0/3
NG-10 M 3/02 0/1 —
NG-11 M 3/02 0/1 0/1
NG-12 M 3/02–4/02 0/2 0/3
NG-13 M 3/02–4/02 0/1 0/3
NG-14 M 3/02 0/1 —
NG-15 M 3/02–4/02 0/2 0/2
NG-16 M 3/02 0/4 —
NG-17 M 3/02 — 0/2
NG-18 M 3/02–4/02 0/1 0/3
NG-19 M 4/02 0/1 0/1
NG-20 M 3/02–4/02 0/1 0/3
NG-21 M 3/02–4/02 0/2 0/3
NG-22 M 3/02–4/02 0/2 —
NG-23 M 3/02 0/1 0/3
NG-24 M 3/02 — 0/1
NG-25 M 3/02 0/1 0/2
NG-26 M 3/02–4/02 0/2 0/2
NG-27 M 3/02 0/4 0/3
NG-28 M 3/02 — 0/2
NG-29 M 3/02–4/02 0/1 0/2
NG-30 M 3/02 0/1 —
NG-31 M 3/02–4/02 0/4 —
NG-32 F 3/02 0/1 —
NG-33 F 4/02 0/1 —
NG-34 M 3/02 — 0/1
NG-35 M 3/02 — 0/2
NG-36 M 3/02–4/02 0/1 0/1
NG-37 M 4/02 0/1 —
NG-38 M 3/02–4/02 0/1 0/1
NG-39 M 4/02 — 0/1
Total 7F/32M 3/02–4/02 0/45 0/58
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forestation and habitat destruction surrounding the National
Park, the Gombe chimpanzees are almost completely isolated
from other east African chimpanzee communities (31).
Analysis of 118 fecal and 81 urine samples from 51 of the 55
Kasekela chimpanzees confirmed infection of the known index
case, Ch-06, and identified one additional SIVcpz-infected
chimpanzee (Table 4). This chimpanzee (Ch-30) is a 32-year-
old, healthy, and sexually active female who has no offspring.
Two urine samples collected in March and April 2002 were
strongly antibody positive, with reactivity to multiple HIV-1
proteins, including core, RT, and envelope glycoproteins and
an overall Western blot profile virtually identical to that of
Ch-06 (Fig. 3). Although two fecal samples collected in De-
cember 2001 and July 2002 were vRNA negative, detection of
high titers of antibodies in urine on two independent occasions
identified Ch-30 as being SIVcpz infected (Table 5).
Two other Kasekela chimpanzees exhibited indeterminant
urine Western blot profiles (Fig. 3). One of these is a healthy
adolescent female, Ch-22, who is believed to have joined the
Kasekela community from Kalande in September 2000 (Table
5). Figure 3 depicts the Western blot profile of a single avail-
able urine sample from Ch-22 which exhibits a very strong p24
reactivity as well as reactivity to p55. Although there was no
detectable reactivity with envelope glycoproteins, this profile
suggests infection, possibly with a divergent SIVcpz exhibiting
little antigenic cross-reactivity in envelope. The second chim-
panzee, Ch-29, is a healthy adult female believed to have
joined Kasekela from Kalande in October 2000 (Table 5). One
of her urine samples also exhibited a distinct p24 band, but this
reactivity was not as strong as the p24 reactivity observed for
Ch-22, and two subsequent urine samples were Western blot
negative (Fig. 3). Thus, the infection status of both Ch-22 and
Ch-29 is uncertain and additional samples will have to be
analyzed.
The documentation of SIVcpz in Kasekela prompted us to
examine members of the neighboring Mitumba community.
Analysis of 22 fecal and nine urine samples from 15 Mitumba
chimpanzees identified two additional SIVcpz-infected apes
(Table 4). Ch-37, a 29-year-old low-ranking male at the time of
study, was repeatedly positive for virus-specific antibodies in
urine (Fig. 3), and Ch-45, a high-ranking 26-year-old male, was
positive for fecal vRNA (Table 5). Ch-37 became chronically ill
and was eventually lost to follow-up in September 2001, thus
precluding confirmation of his infection by amplification of
viral sequences from fecal RNA. By contrast, Ch-45 has re-
mained healthy with no signs of wasting or of other disease.
Two different fecal samples from Ch-45 yielded pol (330 bp)
and gp41/nef (750 bp) fragments, and sequence analysis con-
firmed a new SIVcpz strain, termed TAN3 (Table 5).
Finally, we extended our survey to the southern Kalande
community, screening a total of 25 fecal samples. Although
these were collected from an unknown number of chimpan-
zees, observational data combined with mitochondrial DNA
analysis allowed us to infer that they were derived from at least
10 different individuals. Surprisingly, 3 of the 25 fecal samples
(including one indicating severe diarrhea) were SIVcpz vRNA
positive (Table 4). Since they could have been derived from the
same individual, we amplified and sequenced a 498-bp mito-
chondrial control region (D loop) fragment and compared the
newly derived sequences with other mtDNA sequences from
Gombe as well as reference sequences from the database by
phylogenetic tree analysis (Fig. 4A). This analysis revealed
three distinct mtDNA haplotypes, one for each of the three
SIVcpz-positive fecal samples, indicating that they were indeed
collected from three different individuals (termed Ch-64, Ch-
70, and Ch-71). To determine the sex of these three chimpan-
zees, we amplified a portion of the (nuclear) amelogenin gene.
This gene is known to contain a 189-bp deletion near the
centromere of the Y, but not the X, chromosome (16). Thus,
PCR amplification of a fragment spanning this deletion yields
two PCR products for males (one from the X chromosome
and one from the Y chromosome), but only one product for
females (from the X chromosome). Amplification of such a
fragment from fecal DNA extracted from the three SIVcpz-
infected Kalande chimpanzees (performed in duplicate) iden-
tified Ch-64, Ch-70, and Ch-71 as females (Fig. 4B).
Taken together, of 76 Gombe chimpanzees analyzed, seven
(Ch-06 and Ch-30 from Kasekela; Ch-37 and Ch-45 from Mi-
tumba; and Ch-64, Ch-70, and Ch-71 from Kalande) were
SIVcpz infected, and two (Ch-22 and Ch-29 from Kasekela)
had indeterminant urine antibody results suggestive of SIVcpz
infection.
Prevalence of SIVcpz in Gombe. Using conservative esti-
mates of assay sensitivities determined for SIVcpz-infected
chimpanzees and the numbers and types of specimens actually
analyzed, we calculated the prevalence of SIVcpz infection for
each of the three Gombe communities. These values were 5%
for Kasekela, 17% for Mitumba, and 30% for Kalande. Esti-
mates of the 95% confidence limits showed that for Kasekela,
a total of two infected individuals in the population resulted in
a greater than 5% chance of detecting two or more infected
individuals in the sample set, making 2/55 (4%) the lower
confidence limit on the prevalence in this population. Any
number greater than four infected chimpanzees in the popu-
lation gave a lower than 5% chance of two or fewer infected
chimpanzees being detected, thus making 4/55 (7%) the 95%
upper confidence limit on the prevalence. Corresponding val-
ues for Mitumba were two and eight infected chimpanzees in
the population of 20 individuals, corresponding to confidence
limits of 10 and 40% as the lower and upper bounds, respec-
tively. In Kalande, the range of possible numbers in the com-
munity was from 3 to 12, corresponding to a range of preva-
lences from 15 to 60%.
For the Gombe population as a whole, the mean SIVcpz
prevalence (weighted by population size) was 13%, and the
range indicated by the lower and higher bounds of the indi-
vidual populations was from 7/95 (7%) to 24/95 (25%).
Molecular epidemiology of SIVcpz in Gombe. In addition to
the index chimpanzee Ch-06, four other chimpanzees (Ch-45,
Ch-64, Ch-70, and Ch-71) were found to be fecal vRNA pos-
itive. We thus used RT-PCR approaches to amplify viral se-
quences of sufficient length for phylogenetic analyses. Two
regions of the SIVcpz genome were targeted, a 330-bp pol
fragment in the highly conserved integrase region and a 750-bp
env fragment spanning the junction of gp41 and nef. For Ch-64
and Ch-45, amplification was successful for both regions, and
the corresponding viruses were designated TAN2 and TAN3,
respectively. For the remaining two chimpanzees, only one of
the two genomic regions could be amplified: a pol fragment for
Ch-70 (TAN4) and a gp41/nef fragment for Ch-71 (TAN5). All
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TABLE 4. Noninvasive survey of three wild chimpanzee communities in Gombe National Park, Tanzania
Chimpanzee Sexa Date of samplecollection
Urine samples Fecal samples
Ab pos/no. testedc Ab ID/no. testedd vRNA pos/no. testedb vRNA pos/no. testedb
Kasekela community
Ch-01e F 7/00–4/02 0/3 0/3 0/1 0/4
Ch-02e F 7/00–12/01 0/1 0/1 0/1 0/2
Ch-03e M 7/00–3/02 0/3 0/3 0/1 0/4
Ch-04e M 7/00–12/01 0/2 0/2 0/2 0/3
Ch-05e M 7/00–5/02 0/5 0/5 0/1 0/4
Ch-06e M 7/00–4/02 4/4 0/4 0/2 6/8
Ch-07 M 10/00–4/02 0/3 0/3 0/1 0/3
Ch-08 M 1/01–5/02 0/3 0/3 0/1 0/4
Ch-09 F 7/00–3/02 0/3 0/3 0/1 0/4
Ch-10 M 1/01–3/02 0/2 0/2 0/1 0/2
Ch-11 F 7/00–4/02 0/3 0/3 0/1 0/4
Ch-12 F 11/00–10/01 — — — 0/2
Ch-13 M 8/00–4/02 0/3 0/3 0/1 0/2
Ch-14 M 11/01 — — — 0/1
Ch-15 F 11/01–3/02 0/1 0/1 — 0/3
Ch-16 M 11/00–7/02 0/7 0/7 0/1 0/7
Ch-17 F 11/01 — — — 0/1
Ch-18 F 11/01 — — — 0/1
Ch-19 F 9/01–11/01 0/2 0/2 — 0/1
Ch-20 M 11/00–4/02 0/1 0/1 — 0/3
Ch-21 F 11/01–1/02 — — — 0/2
Ch-22 F 12/01–6/02 0/1 1/1 — 0/4
Ch-23 M 10/00–5/02 0/2 0/2 0/1 0/2
Ch-24 F 12/01–4/02 0/2 0/2 — 0/2
Ch-25 F 11/00–4/02 0/3 0/3 — 0/4
Ch-26 F 12/01 — — — 0/2
Ch-27 M 11/00–4/02 0/3 0/3 0/1 0/3
Ch-28 M 12/01–4/02 0/2 0/2 — 0/1
Ch-29 F 12/01–3/02 0/3 1/3 — 0/4
Ch-30 F 12/01–4/02 2/2 0/2 — 0/2
Ch-31 F 10/00–4/02 0/3 0/3 0/1 0/4
Ch-32 F 12/01–1/02 0/1 0/1 — 0/2
Ch-33 F 10/01–2/02 0/1 0/1 — 0/2
Ch-34 M 1/02; 4/02 0/1 0/1 — 0/1
Ch-35 M 1/02–4/02 0/2 0/2 — 0/2
Ch-36 F 1/02–2/02 0/1 0/1 — 0/2
Ch-40 F 12/01 — — — 0/2
Ch-41 F 1/02 0/1 0/1 — 0/1
Ch-43 F 1/02–4/02 0/3 0/3 — 0/1
Ch-50 F 1/02–4/02 0/2 0/2 — 0/1
Ch-51 M 12/01 — — — 0/1
Ch-52 M 1/02 — — — 0/1
Ch-53 F 12/01 — — — 0/1
Ch-54 M 1/02 — — — 0/1
Ch-55 F 1/02 — — — 0/1
Ch-56 M 1/02 — — — 0/1
Ch-57 F 4/02–7/02 0/2 0/2 — 0/2
Ch-58 M 4/02 — — — 0/1
Ch-60 M 8/02 — — — 0/1
Ch-61 F 4/02 — — — 0/1
Ch-62 M 8/02 — — — 0/1
Total 23M/28F 7/00–8/02 6/81 2/81 0/18 6/119
Mitumba community
Ch-37 M 9/00 4/5 1/5 0/5 —
Ch-38 F 11/01–12/01 — — — 0/2
Ch-39 F 9/00–12/01 0/1 0/1 0/1 0/1
Ch-42 F 10/00–4/02 0/2 0/2 — 0/1
Ch-44 F 10/00–1/02 — — — 0/3
Ch-45 M 1/02 — — — 2/2
Ch-46 F 11/00 — — — 0/1
Ch-47 F 9/00–12/01 0/1 0/1 0/1 0/2
Ch-48 M 12/01; 1/02 — — — 0/2
Ch-49 F 8/02 — — — 0/2
Ch-65 M 3/02 — — — 0/1
Ch-66 F 5/02 — — — 0/2
Ch-67 M 8/02 — — — 0/1
Ch-68 M 8/02 — — — 0/1
Ch-69 M 8/02 — — — 0/1
Total 7M/8F 9/00–8/02 4/9 1/9 0/7 2/22
Continued on facing page
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newly derived sequences were compared to each other as well
as to the previously reported SIVcpz TAN1 strain (48).
In pairwise sequence comparisons, the nucleotide sequences
of all five Gombe SIVcpz strains (TAN1 to TAN5) differed by
5.9 to 9.6% in the pol region and by 9.5 to 14.6% in the
gp41/nef region (Table 6), while pol sequences obtained from
Ch-06 at different time points (TAN1a to TAN1c) differed by
only 0.7 to 1.4% (not shown). When compared to the only
other P. t. schweinfurthii strain, SIVcpzANT, TAN1 to TAN5
differed from by 16 to 21% in the pol and by 40.6% to 43.5%
in the gp41/nef regions, respectively. Thus, the Gombe strains
were much more similar to one another than any one of them
was to SIVcpzANT, but no two were so similar as to suggest
that they represented a direct transmission pair. Phylogenetic
tree analyses confirmed these conclusions, revealing that all
Gombe viruses formed a monophyletic cluster within the
SIVcpzPts radiation (Fig. 5). The extent of divergence among
the Gombe viruses was similar to that seen among HIV-1
group M subtypes (Fig. 5). Since HIV-1 and SIVcpz appear to
have evolved at similar rates (50), this suggests that the com-
mon ancestor of the Gombe SIVcpz strains existed within the
last 100 years. This common ancestor could have resulted from
a single introduction of SIVcpz into the larger Gombe com-
munity. In each tree, it is one of the Kalande strains (TAN4 for
pol, TAN5 for gp41/nef) that forms the outgroup. These rela-
tionships are consistent with an initial introduction into Ka-
lande, followed by onward transmission of the virus to the
other communities. However, additional sequence data are
necessary to confirm this.
DISCUSSION
Noninvasive assay development. Detection of infectious
agents in wild-living, endangered primates is a particular chal-
lenge. Nowhere is this more evident than with SIVcpz infection
of chimpanzees. Field studies of chimpanzees requiring ge-
netic, hormonal, or biochemical analyses have relied on non-
invasively collected hair, urine, or feces (12, 33, 34). We thus
sought to develop urine- and fecal-based methods for SIVcpz
antibody and vRNA detection that would be suitable for viral
testing under field conditions. To accomplish this, assay sensi-
tivities and specificities were first determined in captive chim-
panzees of known infection status. Assay performance was
then evaluated in habituated chimpanzee communities, which
permitted repeated sampling of the same individuals and thus
confirmation of test results. Finally, assays were tested in non-
habituated apes who represent the vast majority of chimpan-
zees in the wild. The combined results from these studies
demonstrate that (i) fecal- and urine-based assays provide suf-
ficient sensitivity and specificity for viral testing under field
conditions; (ii) noninvasive prevalence studies are feasible in
habituated as well as nonhabituated settings; (iii) urine anti-
body screening combined with fecal vRNA amplification and
sequence determination represents the most effective strategy
TABLE 4—Continued
Chimpanzee Sexa Date of samplecollection
Urine samples Fecal samples
Ab pos/no. testedc Ab ID/no. testedd vRNA pos/no. testedb vRNA pos/no. testedb
Kalande community
Ch-64g F 11/01 — — — 1/1
KA-02 F 8/02 — — — 0/1
KA-03 M 6/02 — — — 0/1
KA-04 M 6/02 — — — 0/1
KA-05 M 3/02 — — — 0/1
KA-06 U 4/02 — — — 0/1
KA-07 F 6/02 — — — 0/1
KA-08 U 3/02 — — — 0/1
KA-09 U 8/02 — — — 0/1
KA-10 U 8/02 — — — 0/1
KA-11 U 6/02 — — — 0/1
KA-12 U 4/02 — — — 0/1
KA-13 F 8/02 — — — 0/1
KA-14 U 7/02 — — — 0/1
Ch-70 Ff 3/02 — — — 1/1
KA-16 U 8/02 — — — 0/1
KA-17 U 3/02 — — — 0/1
Ch-71 Ff 6/02 — — — 1/1
KA-19 U 7/02 — — — 0/1
KA-20 M 8/02 — — — 0/1
KA-21 U 5/02 — — — 0/1
KA-22 F 8/02 — — — 0/1
KA-23 U 6/02 — — — 0/1
KA-24 U 6/02 — — — 0/1
KA-25 U 4/02 — — — 0/1
Total  10 11/01–8/02 — — — 3/25
a M, male; F, female; U, unknown.
b Number of vRNA-positive fecal and urine samples per total number tested as determined by diagnostic RT PCR (authenticity of amplification products was
confirmed by sequence analysis). —, specimens not available.
c Number of antibody-positive (Ab pos) urine samples per total number tested as determined by ECL-based immunoblot analysis (see Materials and Methods).
d Number of antibody indeterminant (Ab ID) urine samples per total number tested.
e Individuals included in a previous study (49).
f Sex was determined by PCR amplification of the amelogenin gene (see Materials and Methods).
g Boldface rows indicate chimpanzees confirmed or suspected to be SIVcpz infected.
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to detect with certainty and characterize SIVcpz infection in
the wild; and (iv) these approaches are applicable to other
wild-living endangered primate species (30) (M. Santiago and
B. H. Hahn, unpublished data).
Of the noninvasive methods that we evaluated, the ECL-
based Western blot analysis of urine was by far the most sen-
sitive (95%) in detecting SIVcpz infection. Antibodies in
urine were readily detectable and directed against multiple
viral proteins, with little variation between repeat samples
from the same individual. This was true not only for urine
obtained from captive apes (Fig. 2) but also for samples col-
lected in the wild (Fig. 3). Analysis of antibodies in urine was
also highly specific (100%), since samples from uninfected
chimpanzees did not react with any HIV-1 protein, including
p24 (Fig. 2 and 3). On a practical level, urine antibodies were
stable in the absence of refrigeration. Three urine specimens
from Ch-37 exhibited strong gp160, gp41, and p24 reactivities
despite storage at room temperatures for several weeks after a
freezer breakdown at the Gombe field station (Fig. 3). Finally,
urine contained sufficient quantities of cellular nucleic acids
for host genetic analyses (not shown). Analysis of antibody in
urine thus represents a highly sensitive, specific, and practical
diagnostic tool that can be used in habituated as well as non-
habituated settings. However, insufficient quantities (	1 ml)
can yield false-negative test results. For example, a 200-l
urine aliquot (taken 18 September 2000) from Ch-37 produced
only a single p24 band and thus an indeterminant Western blot
profile (Fig. 3).
In contrast to urine antibody testing, fecal antibody analysis
was found to be only moderately sensitive (60%). Fecal anti-
bodies were generally of lower titer than urine antibodies and
produced more variable banding patterns even when samples
were collected under optimal conditions (Fig. 2). Moreover,
fecal samples required immediate storage at 20°C and ship-
ment on dry ice, thus posing logistical problems at most field
sites. The addition of antibiotics and protease inhibitors at the
time of collection did not improve the sensitivity or reproduc-
ibility of antibody detection (data not shown). Finally, storage
of fecal samples in RNAlater, a preservative of nucleic acids
(see below), precluded antibody analysis. Taken together,
these reasons render fecal antibody testing impractical for
most field settings.
Fecal and urine samples from HIV-1- and SIVcpz-infected
chimpanzees also provided a source of viral RNA (Table 1).
However, the frequency of vRNA detection differed greatly
depending on the types of specimens analyzed (Table 2). Am-
plification of viral sequences from urine was rare for both
HIV-1- and SIVcpz-infected chimpanzees (	10%), suggesting
that virus particles are not normally passed through (or pro-
duced in) intact kidneys. Amplification of viral sequences from
fecal samples of chimpanzees experimentally infected with
HIV-1 was also rare (6%); however, the frequency of vRNA
detection in fecal samples of naturally SIVcpz-infected (cap-
tive) chimpanzees was surprisingly high (56%). Spiking of fecal
samples with known copy numbers of HIV-1 virions revealed
that 104 to 105 virus particles per gram of fecal matter were
required for fecal vRNA detection (data not shown). These
data indicated that most virions were lost during the extraction
FIG. 3. Western blot profiles of urine samples from wild-living chimpanzees. Representative Western immunoblots of urine samples collected
in Kanyawara, Kasekela, and Mitumba are shown; collection dates are indicated (Tables 3 to 5 show details on the particular chimpanzees
analyzed). Molecular weights of HIV-1-specific proteins are indicated. The banding pattern of plasma from an HIV-1-infected human (analyzed
at dilutions of 1:100,000) is shown for positive control.
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and purification step and that high fecal viral loads were re-
quired for successful amplification. Moreover, noninvasive
studies of SIVsm in sooty mangabeys revealed that recovery of
viral RNA sequences from fecal samples depended on high
systemic viral loads and that mangabeys with plasma viral loads
of less than 3,500 particles per ml have a greater than 95%
chance of being fecal vRNA negative (30). These findings
explained the low frequency of fecal vRNA recovery from
HIV-1-infected chimpanzees (Table 2), since most of these
experimentally infected apes had very low or undetectable
plasma virus loads (6, 39, 52). However, it also raised the
question of to what extent SIVcpz-infected wild chimpanzees
could be expected to be fecal vRNA positive. To address this,
we examined the frequency of fecal vRNA detection in the
chimpanzees from Gombe who were either known or sus-
pected to be SIVcpz infected (Table 5). Including all individ-
uals with positive and indeterminant urine antibody results,
this frequency was 11 vRNA-positive fecal samples of 23 tested
(from eight apes) or 49%. Including only the two urine anti-
body-positive individuals, this frequency was 6 of 10 samples,
or 60%. Thus, the frequency of vRNA detection in the feces of
SIVcpz-infected wild chimpanzees appears to be similar to that
of captive SIVcpz-infected chimpanzees as well as SIVsm-
infected sooty mangabeys (30).
Given the importance of fecal samples as a source of viral
sequences, we tested different methods of fecal preservation
previously reported to permit host genetic analyses (12, 15, 56).
These studies showed that fecal treatment with 70% ethanol,
guanidine thiocyanate, or silica did not preserve SIVcpz se-
quences (not shown); however, resuspension in RNAlater
(Ambion), maintained viral as well as cellular nucleic acids,
even in the absence of refrigeration. For example, fecal sam-
ples from Ch-06 shipped at ambient temperature from Tanza-
nia to the United States yielded nucleic acids of sufficient
quality to amplify a complete SIVcpzTAN1 genome (48).
RNAlater also preserved fecal DNA, permitting mtDNA am-
plification (Fig. 4A), microsatellite analyses (not shown), and
amplification of nuclear gene fragments of up to 2,000 bp, such
as portions of the genes encoding amelogenin (Fig. 4B), CCR5,
or glucose-6 phosphate dehydrogenase (not shown). This al-
lowed us to independently confirm the species origin (P. t.
schweinfurthii) of three SIVcpz-positive fecal samples from the
nonhabituated Kalande community and to infer that these
samples were derived from three different females. Unfortu-
nately, RNAlater precludes Western blot analysis of fecal sam-
ples, and attempts to circumvent this problem have thus far
remained unsuccessful.
Endemic SIVcpz infection in Gombe. Our previous finding
of a single SIVcpz-positive chimpanzee (Ch-06) in Kasekela
(49) raised the question of to what extent SIVcpz was prevalent
in this and other Gombe communities. Remarkably, after
screening almost the entire Kasekela community (51 of 55









vRNAc Virus Regionamplified Comments
Confirmed
Ch-06 (KK) 10/77 07/24/00  11/09/00  TAN1(a) pol Mid-ranking male
07/25/00  11/13/00  TAN1(b) pol/gp41
04/11/02  11/18/00  TAN1(c) pol




01/11/02  TAN1(d) gp41
Ch-30 (KK) 03/70 03/31/02  12/13/01  Sterile adult female
04/08/02  07/02/02 





Ch-45 (MI) 07/76 01/03/02  TAN3 pol/gp41 High-ranking male
01/10/02 
Ch-64 (KA) Unknown 03/11/01  TAN2 pol/gp41 Female
Ch-70 (KA) Unknown 03/13/02  TAN4 pol Adolescent female
Ch-71 (KA) Unknown 06/22/02  TAN5 gp41 Female
Suspected
Ch-22 (KK) Unknown 02/10/02 ID 12/14/01  Adolescent female, joined KK 10/00,
presumably from Kalande01/06/02 
06/18/02 
06/20/02 
Ch-29 (KK) Unknown 01/27/02 ID [no date]  Adult female joined KK 9/00,
presumably from Kalande03/10/02  12/13/01 
03/18/02  03/06/02 
06/25/02 
a KK, Kasekela; MI, Mitumba; KA, Kalande.
b WB, Western blot of urine samples; , positive; , negative; ID, indeterminant.
c vRNA, detection of SIVcpz vRNA in fecal samples.
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individuals, 93%), only one other SIVcpz-infected chimpan-
zee, Ch-30, was identified. Prevalence calculation based on the
types and numbers of samples tested predicted a 5% infection
rate for this community, with a 95% confidence interval of 4 to
7%. However, the actual prevalence may be closer to the upper
limit since two chimpanzees with indeterminant urine Western
blot results were considered negative in these calculations (Fig.
3). One of these, an adolescent female, Ch-22, believed to have
joined Kasekela from the southern Kalande community, is
likely to be SIVcpz infected since her urine Western blot pro-
file showed reactivity with two structural proteins (p24 and
p55). The second chimpanzee, an adult female, Ch-29, also
believed to have originated from Kalande, is more difficult to
assess since only one of three urine samples exhibited a single
p24 band (Fig. 3). Analyses of additional urine (and fecal)
samples will be required to determine whether this p24 reac-
tivity is unspecific, indicative of a low-titer antibody response,
or the result of infection with a more divergent (antigenically
less cross-reactive) virus. Urine antibody testing using Western
blot strips containing SIVcpz antigens derived from a cognate
P. t. schweinfurthii virus should aid in distinguishing between
these possibilities.
We also screened the neighboring Mitumba and Kalande
chimpanzees. In the northern Mitumba community, we iden-
tified two males as harboring SIVcpz. With 15 of the 20 indi-
viduals tested, this accounts for a prevalence estimate of 17%.
Since most Mitumba chimpanzees were tested for fecal vRNA
only, the confidence interval is wide, ranging from 10 to 40%.
In the southern Kalande community, three SIVcpz-infected
females were identified, accounting for a prevalence of 30%,
again with a wide confidence interval (15 to 60%). This prev-
alence is the highest of all Gombe communities and suggests a
hot spot of SIVcpz infection in Kalande. The fact that two
Kasekela chimpanzees with indeterminant Western blot results
(Ch-22 and Ch-29) originated in Kalande, along with the phy-
logenetic data suggesting Kalande as the point of origin for the
Gombe infections (Fig. 5), are consistent with this interpreta-
tion.
Although the phylogenetic relationships of the five Gombe
strains indicate passage of virus among the three communities
(Fig. 5), the routes of SIVcpz transmission remain unknown.
To date, we have not been able to document sexual transmis-
sion. Similarly, we have not been able to assess vertical trans-
mission because the females known or suspected to be infected
are either infertile (Ch-30), adolescent (Ch-22), recent immi-
grants (Ch-29), or not habituated (Ch-64, Ch-70, and Ch-71).
FIG. 4. Subspecies and sex determination of three SIVcpz-infected, nonhabituated chimpanzees from Kalande. (A) Phylogenetic tree of
mitochondrial DNA sequences. D-loop sequences (498 bp) amplified from three SIVcpz vRNA-positive fecal specimens (boxed) from Kalande
were compared with mtDNA sequences from other eastern chimpanzees (P. t. schweinfurthii). The mtDNA sequence for Ch-No has been reported
previously (18). Sequences for Ch-06, Ch-22, Ch-45, Ch-37, Ch-30, and Ch-Ni have been determined in this study. The tree was obtained by
maximum likelihood analysis of 377 gap-stripped sites by using the REV Gamma substitution model implemented in BASEML from the PAML
package (PAML, software version 3.0b; University College London, London, United Kingdom) testing 48 tree topologies obtained from NUCML
from the MOLPHY package (program package for MOLecular PHYlogenetics, software version 2.2; Institute of Statistical Mathematics, 4-6-7
Minami-Azabu, Minato-ku, Tokyo 106, Japan). Asterisks denote clades to the right found in at least 70% of bootstrapped replicates analyzed by
the neighbor-joining method implemented in CLUSTAL W (53) using Kimura’s two-parameter correction (27). The three Kalande sequences
(boxed) represent different haplotypes within the P. t. schweinfurthii radiation, indicating that the samples came from three different individuals.
Ch-30 and Ch-37 (in parentheses) have haplotypes identical to those of Ch-64 and Ch-45, respectively. The tree is rooted on sequences from the
subspecies P. t. verus and P. t. vellerosus. (B) Sex determination of Ch-64, Ch-70, and Ch-71 from Kalande. A region of the amelogenin gene, known
to contain a 189-bp deletion near the centromere of the Y, but not the X, chromosome, was amplified (16). Fecal DNA from known male (Ch-06,
Ch-05, and Ch-16) and female (Ch-09, Ch-25, and Ch-01) chimpanzees from Kasekela was analyzed for control. Sex determination for Ch-64,
Ch-70, and Ch-71 was performed in duplicate.
TABLE 6. Percent nucleotide sequence differences between pol and
gp41/nef regions of Gombe SIVcpz strains
Virus strain
% nucleotide sequence difference, pol and gp41/nef regions
TAN1 TAN2 TAN3 TAN4a TAN5a ANT
TAN1 6.6 9.1 8.7 — 21.0
TAN2 13.0 5.9 9.6 — 19.9
TAN3 13.9 9.5 8.7 — 19.2
TAN4a — — — — 16.1
TAN5a 13.8 14.6 14.4 — —
ANT 41.6 40.6 43.3 — 43.5
a —, sequences not available.
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Finally, there has been no information to link the observed
infections to border fights which are sometimes violent and
thus represent a plausible route of transmission. An extreme
example occurred in 1974, when border fights between Kase-
kela and neighboring Kahama males led to the dissolution of
the entire Kahama community and the death of all Kahama
males (23). Analysis of all chimpanzees who have not yet been
tested, especially those in Mitumba and Kalande, as well as the
molecular characterization of all circulating viruses, will be
necessary to decipher the transmission patterns of SIVcpz
within and between the Gombe communities and to elucidate
why the two smallest communities seem to have a dispropor-
tionate number of infected individuals.
Absence of SIVcpz infection from Kibale? In light of the
seven documented and two suspected cases of SIVcpz infec-
tion in Gombe chimpanzees, the failure to find infection
among the 70 chimpanzees from Ngogo and Kanyawara
came as a surprise. We therefore examined the possibility that
SIVcpz infection existed in Kibale but went undetected. We
asked three questions. (i) What is the likelihood that any par-
ticular chimpanzee could have been infected despite negative
test results, given the numbers and types of specimens analyzed
and the sensitivities of the respective assays? (ii) What is the
likelihood that one chimpanzee in each of the two groups
studied was infected? (iii) What inferences can be drawn about
the likely prevalence of SIVcpz in the larger Kibale commu-
nities surrounding and including the Ngogo and Kanyawara
study groups?
The likelihood of a negative test result despite true infection
in any one chimpanzee studied in Kanyawara was very low,
ranging from 0.043 for chimpanzees for which only a single
urine sample was tested to 	0.001 for chimpanzees for which
four or more urine samples were analyzed. In Ngogo, the
likelihood of a falsely negative test ranged from 0.44 for chim-
panzees for which only a single fecal sample was tested to
	0.001 for individuals for which four urine samples were an-
alyzed. Assuming there actually had been a single infected
chimpanzee among those tested in Kibale, the chance of hav-
ing missed this individual was 1.8% in Kanyawara and 8.2% in
Ngogo, respectively. These values reflect the fact that a con-
servative estimate of urine antibody detection sensitivity (0.95)
was used, and that in Ngogo, 8 of 39 individuals had only fecal
samples available for testing. Finally, within the larger Kibale
population (assuming an unlimited population size), we could
exclude the possibility of a 10% or higher prevalence rate with
95% certainty. However, the possibility of a 1% or lower prev-
alence could not be ruled out. In fact, the probability of having
missed a 1% prevalence was estimated to be 49%. Thus, a low-
level endemic infection of the larger Kibale population of
chimpanzees certainly remains a possibility.
P. t. schweinfurthii represents an atypical SIV reservoir. The
finding of endemic infection in Gombe identifies P. t. schwein-
furthii as a natural host and reservoir for SIVcpz; however, the
observed frequencies and distribution of infection indicate that
naturally infected apes differ from SIV-infected monkey spe-
cies in fundamental ways. First, the great majority of these
monkey species harbor SIV at much higher frequencies (5, 11,
14, 25, 40, 43). Surveys of primate bushmeat as well as wild-
living populations have yielded infection rates of greater than
40% for most of these species. Second, SIV infection is more
uniformly distributed among members of these various species.
Random sampling at any site within the natural range seems to
be sufficient to identify SIV-infected animals (1, 4, 5, 14, 40,
43). Third, field studies of wild grivets and sabaeus monkeys
have shown that SIV infection rates increase with age and that
90% of sexually active females can be infected. This has been
taken to indicate that SIV is transmitted in these communities
predominantly by sexual routes (5, 43). SIVcpz infection in
Gombe does not increase with age, nor is it preferentially
found in multiparous females—and this is not due to a lack of
sexual activity. For example, Ch-06 has mated at least 333
times with 25 different females since puberty. More impor-
tantly, since July 2000, the earliest date of his SIVcpz diagnosis,
Ch-06 has mated at least 33 times with eight females, and none
FIG. 5. Phylogenetic analyses of SIVcpz in Gombe. Five different SIVcpz strains identified in Mitumba, Kasekela, and Kalande were analyzed
in two different genomic regions, a 286-bp pol and 564-bp gp41/nef fragment (after gap stripping). The newly derived sequences TAN2, TAN3,
TAN4, and TAN5 were compared with TAN1 sequences from different time points (Table 5) as well as reference sequences for HIV-1 M subtype
A; U455 (GenBank accession number M62320), subtype B; LAI (K02013), subtype D; ELI (K03454), HIV-1 N; YBF30 (AJ006022), HIV-1 O;
MVP5180 (L20771), and ANT70C (L20587), SIVcpz; CAM3 (AF115393), CAM5 (AJ271369), US (AF103818), GAB1 (X52154), and GAB2 (F.
Bibollet-Ruche and B. H. Hahn, unpublished data), and ANT (U42720). The trees were obtained by the neighbor-joining method (47)
implemented in CLUSTAL W (53) by using Kimura’s two-parameter correction (27) and 1,000 bootstrapped replicates. Asterisks indicate that the
clades to the right were found in at least 80% of bootstrapped replicates.
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have become infected. These data suggest that transmission of
SIVcpz by sexual and/or other routes is much less efficient than
transmission of SIV in smaller monkey species. Although the
reasons for this remain unknown, it is of interest that hetero-
sexual transmission of HIV-1 in humans is also very inefficient,
ranging from 1 in 250 to 1 in 3,000 per unprotected coital act
(17, 24, 45, 46). Thus, chimpanzees seem to resemble humans
more than monkeys in the frequency with which they transmit
SIV.
Assuming that natural transmission of SIVcpz is rare, how
can the observed differences in SIVcpz prevalence in Kibale
and Gombe be reconciled? Studies of HIV-1 infection rates in
remote rural human populations may provide an answer. In
1986, Nzilambi and colleagues found an HIV-1 prevalence of
0.8% in a rural population of the Equateur province of the
Democratic Republic of the Congo (formerly Zaire) (37).
Moreover, retrospective analysis of blood samples obtained in
1976 from this same population revealed that the frequency of
HIV-1 infection had not changed over a 10-year time period
(37). If HIV-1 infection can be sustained in a heterosexual
human population at low frequencies (	1%), the same may be
true for SIVcpz infection of chimpanzees. Under this scenario,
a low-level rate of SIVcpz endemicity would be the rule, while
much higher prevalence rates like those seen in Gombe would
be the exception, possibly resulting from higher transmission
rates in an increasingly isolated population. Screening of ad-
ditional chimpanzees in Kibale in sufficient numbers to detect
a 1% or lower prevalence rate will be necessary to address this
possibility.
Alternatively, Kibale chimpanzees may have never been ex-
posed to SIVcpz because of biogeographic divisions of the
eastern chimpanzee population. Kibale National Park is ap-
proximately 500 km north of Gombe National Park (Fig. 1A).
Intervening lacustrine and forest gap barriers may have limited
gene flow between these populations in the past (19, 20). It is
possible that SIVcpz infection may not have spread to Kibale
if it was introduced into eastern chimpanzee populations sub-
sequent to the establishment of such gene flow barriers. This
hypothesis can be tested by screening chimpanzee communi-
ties on either side of putative biogeographic barriers, such as
populations north (Budongo, Semliki, and Bugoma) and south
(Nyungwe and Mahale) of the Kazinga Channel (between
Lake George and Lake Edward in Uganda).
Still another possibility is that SIVcpz may have been pres-
ent in the Kibale chimpanzees at some point in time but sub-
sequently became extinct. Although a combination of biologi-
cal, ecological, and epidemiologic factors, including stochastic
events, could have been responsible for such an event, the fact
that the Kibale population is much larger than the one in
Gombe makes this possibility somewhat less likely. Finally, the
unexpected irregular pattern of SIVcpz infection described
here for Kibale and Gombe may be unique to P. t. schwein-
furthii at the easternmost limits of their range, possibly reflect-
ing a particularly fragmented habitat. Studies of P. t. schwein-
furthii communities elsewhere, for example in the Democratic
Republic of the Congo, will be necessary to address this pos-
sibility.
P. t. schweinfurthii is not the source of pandemic HIV-1.
Phylogenetic analyses of all known SIVcpz and HIV-1 strains,
including the newly identified Gombe viruses, show quite
clearly that SIVcpz from P. t. schweinfurthii was not responsible
for the human AIDS pandemic (Fig. 5) (48, 49, 50). Instead,
several lines of evidence implicate west central African P. t.
troglodytes apes as the source of HIV-1 groups M, N, and O (2,
13, 18, 25). The findings of this report point to the importance
of field studies in west central Africa to determine the molec-
ular epidemiology and prevalence of SIVcpz in this area. The
present study demonstrates the feasibility of such an undertak-
ing and provides a frame of reference for future studies of
SIVcpz natural history, epidemiology, and evolution.
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